3.37

1.17% -0.04

Arbutus Biopharma Corp (ABUS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arbutus Biopharma Corp stock is traded at $3.37, with a volume of 1.81M. It is down -1.17% in the last 24 hours and up +4.66% over the past month. Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Previous Close:

$3.41

Open:

$3.43

24h Volume:

1.81M

Relative Volume:

2.00

Market Cap:

$679.92M

Revenue:

$12.99M

Net Income/Loss:

$-74.39M

P/E Ratio:

-7.6591

EPS:

-0.44

Net Cash Flow:

$-78.92M

1W Performance:

-2.32%

1M Performance:

+4.66%

6M Performance:

+5.97%

1Y Performance:

+9.77%

1-Day Range:

$3.36

$3.475

1-Week Range:

$3.29

$3.54

52-Week Range:

$2.705

$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name

Arbutus Biopharma Corp

Sector

Healthcare (1170)

Industry

Biotechnology (661)

Phone

604-419-3200

Address

701 VETERANS CIRCLE, WARMINSTER, PA

Employee

Twitter

@arbutusbio

Next Earnings Date

2025-03-26

Latest SEC Filings

ABUS's Discussions on Twitter

Compare ABUS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABUS Arbutus Biopharma Corp	3.37	679.92M	12.99M	-74.39M	-78.92M	-0.44
VRTX Vertex Pharmaceuticals Inc	450.27	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	522.27	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	325.00	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	568.06	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	266.80	28.51B	3.81B	-644.79M	-669.77M	-6.24

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Initiated	Jefferies	Hold
Dec-17-20	Initiated	H.C. Wainwright	Buy
Jul-27-20	Resumed	JMP Securities	Mkt Outperform
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-20-20	Initiated	Robert W. Baird	Outperform
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Oct-07-19	Reiterated	B. Riley FBR	Buy
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral
Oct-12-18	Reiterated	Chardan Capital Markets	Buy
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Mar-19-18	Resumed	Chardan Capital Markets	Buy
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-01-17	Reiterated	Wedbush	Outperform
Dec-13-16	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-30-16	Upgrade	Chardan Capital Markets	Neutral → Buy

View All

Arbutus Biopharma Corp Stock (ABUS) Latest News

Jun 13, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025

Jun 08, 2025

Ameriprise Financial Inc. Makes New $62,000 Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jun 08, 2025

Jun 07, 2025

Bank of America Corp DE Acquires 171,906 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jun 07, 2025

Jun 05, 2025

Millennium Management LLC Purchases 92,068 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jun 05, 2025

May 29, 2025

Deutsche Bank AG Buys 75,212 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 29, 2025

May 22, 2025

Northern Trust Corp Has $4.35 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 22, 2025

May 18, 2025

Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress - MyChesCo

May 18, 2025

Mercer Global Advisors Inc. ADV Makes New Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 18, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025

May 15, 2025

Arbutus: Q1 Earnings Snapshot - CT Insider

May 15, 2025

May 14, 2025

Arbutus Biopharma Corp Reports Q1 2025 Earnings: Revenue at $1.8 Million, EPS Misses Estimate with $0.13 Loss - GuruFocus

May 14, 2025

Arbutus Biopharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada

May 14, 2025

Arbutus Biopharma (ABUS) Reports Mixed Q1 Results - GuruFocus

May 14, 2025

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 14, 2025

Arbutus (ABUS) Reports Lower Q1 Revenue Amid Promising Treatment Progress | ABUS Stock News - GuruFocus

May 14, 2025

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 14, 2025

May 13, 2025

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

May 13, 2025

May 10, 2025

Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 - MyChesCo

May 10, 2025

May 08, 2025

Wells Fargo & Company MN Acquires 21,768 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 08, 2025

May 07, 2025

Arbutus Biopharma (ABUS) Showcases Promising Data on Imdusiran and AB-101 | ABUS Stock News - GuruFocus

May 07, 2025

Arbutus Presents Clinical Trial Data from its Two HBV - GlobeNewswire

May 07, 2025

May 06, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Barclays PLC - Defense World

May 06, 2025

May 05, 2025

Invesco Ltd. Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 05, 2025

May 02, 2025